RD-001

RD-001 is a preclinical-stage vaccine adjuvant being developed by MegaPro Biomedical. It is intended to be formulated with vaccine antigens to potentiate the host's immune response, potentially increasing the efficacy and duration of protection provided by the vaccine. MegaPro Biomedical's core expertise lies in the development of iron oxide nanoparticles (IOP) with functional surface coatings for targeted delivery and diagnostic imaging. While RD-001 is categorized as a vaccine adjuvant within the company's pipeline, specific details regarding its chemical composition, whether it utilizes the company's nanoparticle platform, or its specific immunological targets remain proprietary and have not been disclosed.